1. MillerAB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment.Am J Cancer 1981; 47: 207–14.
2. Mulé JJ,Rosenberg SA. Interleukin-2: Pre-clinical trials. In: De Vita VT, Hellman S, Rosenberg SA, editors. Biologic Therapy ofCancer. London: JB Lippincott Co, 1991; 142–58.
3. Pinsky CM.Applicability of phase I trial results in the design of phase II and IIIbiological response modifier trials. Cancer Treat Rep 1985; 69: 1171–3.
4. Jones M, Selby P, Bradley C, et al. Advanced renal cancer treated byinterleukin-2 continuous infusion:comparison of survival to a matched control group. The 2nd Intl Symposium -Immunobiology of RCC, Cleveland Clinic 1991; 20: 136.
5. Lotze MT. Interleukin-2: Basic principles. In: De Vita VT, Hellman S,Rosenberg SA, editors. BiologicTherapy of Cancer. London: JB Lippincott Co, 1991; 123–41.